Because I promised my granddaughter more days like this.

Our commitment starts here.
Find. Fight. Follow.

Because better insights mean better decision-making.

Our commitment starts here.
Find. Fight. Follow.

Because their lives are in our hands.

Our commitment starts here.
Find. Fight. Follow.

$83.50
+0.19
NASDAQ | LNTH (Common Stock)

Data provided by Nasdaq.
Minimum 15 minutes delayed.

Visit Investor Site

For more than half a century, our diagnostic and therapeutic innovations have changed the way clinicians Find, Fight and Follow® disease. Today, we go further still—with the same sense of purpose and commitment to empowering healthcare professionals with life-changing science that helps improve outcomes and lives.

Our History

News & Media

08/04/22

Lantheus Reports Second Quarter 2022 Financial Results

Worldwide revenue of $223.7 million for the second quarter 2022, representing an increase of 121.4% from the prior year period GAAP net income of $43.1 million for the second quarter 2022, compared to GAAP net loss of $26.7 million in the prior year period GAAP fully diluted net income per share of

Read More
07/21/22

Lantheus Holdings to Host Second Quarter 2022 Earnings Conference Call and Webcast on August 4, 2022, at 8:00 a.m. Eastern Time

NORTH BILLERICA, Mass. , July 21, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, August 4, 2022 , to discuss its financial and operating results for the second quarter of

Read More
06/15/22

Lantheus Announces Promotion of Paul Blanchfield to Chief Operating Officer

Dottie Barr Promoted to Senior Vice President, Manufacturing and Technical Operations NORTH BILLERICA, Mass. , June 15, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH), today announced two key management promotions. Paul Blanchfield has been promoted to Chief

Read More
06/13/22

Lantheus Highlights Preliminary Study Results Demonstrating Potential of NM-01, a Novel Technetium-99m SPECT/CT Imaging Agent, to Assess PD-L1 Expression for Immunotherapy in Cancer

Study Results Presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting NORTH BILLERICA, Mass. , June 13, 2022 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“the Company”) (NASDAQ: LNTH) is committed to improving patient outcomes through diagnostics, radiotherapeutics

Read More